Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kohen, D.
and
Bristow, M. F.
1999.
Atypical antipsychotics and neuroleptic malignant syndrome.
British Journal of Psychiatry,
Vol. 175,
Issue. 4,
p.
392.
Sajatovic, Martha
Madhusoodanan, Subramoniam
and
Buckley, Peter
2000.
Schizophrenia in the Elderly.
CNS Drugs,
Vol. 13,
Issue. 2,
p.
103.
Meisenzahl, E. M.
Dresel, S.
Frodl, T.
Schmitt, G. J. E.
Preuss, U. W.
Rossmüller, B.
Tatsch, K.
Mager, T.
Hahn, K.
and
Möller, H. -J.
2000.
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Journal of Psychopharmacology,
Vol. 14,
Issue. 4,
p.
364.
Mikhail, SW
and
Kennedy, HG
2000.
Homicide, novel antipsychotics, and non-compliance.
The Lancet,
Vol. 355,
Issue. 9210,
p.
1189.
Balestrieri, Matteo
Vampini, Claudio
and
Bellantuono, Cesario
2000.
Efficacy and safety of novel antipsychotics: a critical review.
Human Psychopharmacology: Clinical and Experimental,
Vol. 15,
Issue. 7,
p.
499.
Kontaxakis, V.P.
Havaki-Kontaxaki, B.J.
Christodoulou, N.G.
Paplos, K.G.
and
Christodoulou, G.N.
2000.
Olanzapine-induced neuroleptic malignant syndrome.
European Neuropsychopharmacology,
Vol. 10,
Issue. ,
p.
312.
Gervin, Maurice
and
Barnes, Thomas R.E.
2000.
Assessment of drug-related movement disorders in schizophrenia.
Advances in Psychiatric Treatment,
Vol. 6,
Issue. 5,
p.
332.
Weiser, Mark
Shneider-Beeri, Michal
Nakash, Nitza
Brill, Noa
Bawnik, Odelia
Reiss, Shoshana
Hocherman, Shraga
and
Davidson, Michael
2000.
Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?.
Schizophrenia Research,
Vol. 46,
Issue. 2-3,
p.
81.
Kelly, Brendan D.
and
Shanley, David
2000.
Terminal Illness and Schizophrenia.
Journal of Palliative Care,
Vol. 16,
Issue. 2,
p.
55.
Mouallem, Meir
and
Wolf, Ido
2001.
Olanzapine-Induced Respiratory Failure.
The American Journal of Geriatric Psychiatry,
Vol. 9,
Issue. 3,
p.
304.
Crews, Cynthia K.
2001.
Medical Care of Persons With Severe Mental Illness.
Primary Care Case Reviews,
Vol. 4,
Issue. 3,
p.
103.
Poyurovsky, Michael
and
Weizman, Abraham
2001.
Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: A new approach to an old problem.
British Journal of Psychiatry,
Vol. 179,
Issue. 1,
p.
4.
Stubbs, Jean
and
Haw, Camilla
2001.
Medication, Schizophrenia and the Forensic Multidisciplinary Team.
The British Journal of Forensic Practice,
Vol. 3,
Issue. 4,
p.
29.
Bozikas, V.
Petrikis, P.
and
Karavatos, A.
2001.
Urinary retention caused after fluoxetine–risperidone combination.
Journal of Psychopharmacology,
Vol. 15,
Issue. 2,
p.
142.
Curran, Stephen
Harris, Linda
Macdonald, Andrew
Pollock, Colin
Roney, Gerry
and
Silkstone, David
2002.
Antipsychotics in clinical practice: guidelines for safe and effective use.
Human Psychopharmacology: Clinical and Experimental,
Vol. 17,
Issue. 2,
p.
75.
Kontaxakis, Vassilis P.
Havaki-Kontaxaki, Beata J.
Stamouli, Sophia S.
and
Christodoulou, George N.
2002.
Toxic interaction between risperidone and clozapine: A case report.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 26,
Issue. 2,
p.
407.
Kulhanek, F.
2002.
Fortschritte in Psychiatrie und Psychotherapie.
p.
51.
Harris, N. R.
Lovell, K.
and
Day, J. C.
2002.
Consent and long‐term neuroleptic treatment.
Journal of Psychiatric and Mental Health Nursing,
Vol. 9,
Issue. 4,
p.
475.
Gluais, Pascale
Bastide, Michèle
Caron, Jacques
and
Adamantidis, Monique
2002.
Risperidone prolongs cardiac action potential through reduction of K+ currents in rabbit myocytes.
European Journal of Pharmacology,
Vol. 444,
Issue. 3,
p.
123.
McAllister-Williams, R. Hamish
and
Ferrier, I. Nicol
2002.
Rapid tranquillisation: Time for a reappraisal of options for parenteral therapy.
British Journal of Psychiatry,
Vol. 180,
Issue. 06,
p.
485.
eLetters
No eLetters have been published for this article.